Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,291 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastro-Intestinal Cancer Clear all

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions: KPT-8602, ASTX727, Dexamethasone; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 26
States / cities: Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more

Conditions: Breast Cancer, Colon Cancer
Interventions: Eniluracil; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Colorectal Cancer, Colorectal Neoplasms
Interventions: Epi proColon; Device
Lead sponsor: Epigenomics, Inc; Industry
Eligibility: 50 Years to 74 Years
Enrollment: 4,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: San Diego, California • Royal Oak, Michigan • New Brunswick, New Jersey + 3 more

Conditions: Pancreatic Cancer, GastroEsophageal Cancer, Rectal Cancer, Head and Neck Cancer, Lymphoma
Interventions: Supportive Oncology Care at Home, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor, Colorectal Cancer, Endometrial Cancer
Interventions: DS-7423; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Detroit, Michigan • New York, New York • Nashville, Tennessee

Conditions: Colo-rectal Cancer, Rectal Prolapse, Colostomy Stoma, Colorectal Disorders
Interventions: Single port robotic colorectal surgical procedure; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Metastatic Colorectal Cancer
Interventions: Selinexor, Pembrolizumab, Trifluridine, Tipiracil; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Los Angeles, California • Newark, Delaware • Plantation, Florida

Conditions: Cancer
Interventions: BMS-911543; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Houston, Texas

Conditions: Colorectal Cancer
Interventions: Interviews - Colorectal Cancer Participants, Questionnaire, Focus Groups, Interviews - Caregivers of Colorectal Cancer Participants; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Houston, Texas

Conditions: Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Interventions: Online modality, Genetic counselor follow-up; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Microsatellite Stable Metastatic Colorectal Cancer
Interventions: Evorpacept (ALX148), Cetuximab, Pembrolizumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Tucson, Arizona • Aurora, Colorado • New Brunswick, New Jersey + 1 more

Conditions: Colorectal Cancer
Interventions: bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Cancer, Refractory Cancer, Tumor Gastric
Interventions: PCS6422 and capecitabine; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Omaha, Nebraska • New Brunswick, New Jersey • Santa Fe, New Mexico + 3 more

Conditions: Gastrointestinal Cancer, Gastrointestinal Tumor, Gastrointestinal Tumor Surgery, Gastrointestinal Surgery
Interventions: Voice-Assisted Remote Symptom Monitoring System (VARSMS); Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Omaha, Nebraska

Conditions: Metastatic Colorectal Cancer
Interventions: ZN-c3, Encorafenib, Cetuximab; Drug
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • Merriam, Kansas • Houston, Texas

Conditions: Gastrointestinal Neoplasms, Gastric Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Gastric Cancer
Interventions: bortezomib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 4
States / cities: Chicago, Illinois • Jamaica, New York • New York, New York + 1 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions: AFNT-211; Drug
Lead sponsor: Affini-T Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Floxuridine, Intrahepatic Infusion Procedure, Leronlimab, Magnetic Resonance Imaging, Surgical Procedure, Systemic Therapy; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Goodyear, Arizona • Duarte, California • Irvine, California

Conditions: Adenocarcinoma of the Esophagus
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Cancer, Lung Cancer
Interventions: positron emission tomography, fludeoxyglucose F 18; Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
Interventions: PCR/PCR/LDR Strategy; Genetic
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 21,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Rectal Cancer, Non Metastatic Rectal Cancer
Interventions: Quality of Life Surveys; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Eniluracil Hand Foot Syndrome

Longitudinal Performance of Epi proColon

Supportive Oncology Care At Home RCT

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Multiple Ascending Dose of BMS-911543

Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer

Scalable Communication Modalities for Returning Genetic Research Results

Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

REmote Symptom COllection to improVE postopeRative Care

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Endoscopic Submucosal Dissection Registry

Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial

Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Leveraging Digital Health Solutions to Collect Patient-Reported Outcomes in Rectal Cancer